Avalyn Pharma Inc. executive Carlson Douglas R filed an initial Form 3 showing stock option holdings in the company. He holds options to acquire 83,576 shares of common stock at an exercise price of $4.81 per share, expiring on September 10, 2035, and options on 270,498 shares at $4.62 per share, expiring on June 10, 2034.
For the $4.81 options, 25% of the underlying shares vested on May 1, 2025, with the remaining 75% vesting in 36 equal monthly installments, subject to continued service. For the $4.62 options, 25% vest on May 29, 2026, with the balance also vesting in 36 monthly installments, contingent on his continued service.
Avalyn Pharma Inc. filed an initial insider ownership report for its General Counsel, Adam H. Golden. The Form 3 lists him as an officer but does not report any share transactions or derivative positions, indicating this filing is purely administrative disclosure of insider status rather than trading activity.